| scholarly article | Q13442814 |
| P356 | DOI | 10.1016/S0169-5002(98)00086-5 |
| P698 | PubMed publication ID | 10048471 |
| P50 | author | Jeffrey A Kern | Q63373813 |
| P2093 | author name string | Y C Kim | |
| S C Lim | |||
| C S Park | |||
| A S Jang | |||
| J B Yang | |||
| K O Park | |||
| P2860 | cites work | C-erbB-2 expression and codon 12 K-ras mutations both predict shortened survival for patients with pulmonary adenocarcinomas. | Q34124421 |
| DNA ploidy and proliferative activity in bcl-2 expressed non-small cell lung cancer | Q35938738 | ||
| Bcl-2 protein: a prognostic factor inversely correlated to p53 in non-small-cell lung cancer | Q36080901 | ||
| Expression of the BCL-2 protein in normal and dysplastic bronchial epithelium and in lung carcinomas | Q38480548 | ||
| Prognostic significance of the expression ofras oncogene product in non-small cell lung cancer | Q38488364 | ||
| United States lung carcinoma incidence trends: declining for most histologic types among males, increasing among females | Q38506876 | ||
| The use of avidin-biotin interaction in immunoenzymatic techniques | Q39563816 | ||
| Changing trends in histologic types of lung cancer during the last decade (1981-1990) in Korea: a hospital-based study | Q40697028 | ||
| The relationship of p53 immunostaining to survival in carcinoma of the lung | Q42125689 | ||
| bcl-2 protein in non-small-cell lung carcinoma | Q42508274 | ||
| Chemotherapy and surgery versus surgery alone in non-small-cell lung cancer | Q45237878 | ||
| The new International Staging System for Lung Cancer. | Q53418950 | ||
| Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer | Q53494420 | ||
| Prognostic value of c-erbB-2 protein expression in human lung adenocarcinoma and squamous cell carcinoma | Q58454772 | ||
| K-ras oncogene activation as a prognostic marker in adenocarcinoma of the lung | Q68532141 | ||
| Expression of p53 oncoprotein in non-small-cell lung cancer: a favorable prognostic factor | Q71961895 | ||
| Recent cancer trends in the United States | Q72134624 | ||
| Altered retinoblastoma protein expression and prognosis in early-stage non-small-cell lung carcinoma | Q72365281 | ||
| P433 | issue | 3 | |
| P921 | main subject | non-small-cell lung carcinoma | Q3658562 |
| P304 | page(s) | 181-190 | |
| P577 | publication date | 1998-12-01 | |
| P1433 | published in | Lung Cancer | Q641464 |
| P1476 | title | The interactive effect of Ras, HER2, P53 and Bcl-2 expression in predicting the survival of non-small cell lung cancer patients | |
| P478 | volume | 22 |
| Q73793628 | Apoptosis and bcl-2 expression as predictors of survival in radiation-treated non-small-cell lung cancer |
| Q36072192 | Association of HER-2 overexpression with prognosis in nonsmall cell lung carcinoma: a metaanalysis |
| Q48540510 | Association of Ki-67, p53, and bcl-2 expression of the primary non-small-cell lung cancer lesion with brain metastatic lesion |
| Q40660285 | Biological parameters on computed tomography guided fine needle aspiration biopsy from peripheral primary non-small cell lung cancer |
| Q73955113 | Biological variables in non-small cell lung cancer: comparison between immunocytochemical determination on fine needle aspirates from surgical specimens and immunohistochemical determination on tissue sections |
| Q45976336 | Bortezomib plus docetaxel in advanced non-small cell lung cancer and other solid tumors: a phase I California Cancer Consortium trial. |
| Q34936052 | Clinical impact of novel treatment strategies |
| Q35008670 | Clinical relevance of molecular markers in lung cancer. |
| Q55283405 | Expression of Bcl-2 is a favorable prognostic biomarker in lung squamous cell carcinoma. |
| Q64971959 | Future Options of Molecular-Targeted Therapy in Small Cell Lung Cancer. |
| Q55090683 | HER2 is frequently over-expressed in ovarian clear cell adenocarcinoma: possible novel treatment modality using recombinant monoclonal antibody against HER2, trastuzumab. |
| Q33575266 | High expression of BCL-2 predicts favorable outcome in non-small cell lung cancer patients with non squamous histology |
| Q77530352 | In vivo expression of p53 and Bcl-2 and their role in programmed cell death in premalignant and malignant lung lesions |
| Q33194582 | Loss of heterozygosity of chromosome 12p does not correlate with KRAS mutation in non‐small cell lung cancer |
| Q47782716 | Measurement of chemoresistance markers in patients with stage III non-small cell lung cancer: a novel approach for patient selection |
| Q34427045 | Molecular pathology of tumor metastasis. I. Predictive pathology |
| Q34679340 | Non-small cell lung cancer clinical trials with trastuzumab: their foundation and preliminary results |
| Q33944623 | Prognostic significance of thymidylate synthase in postoperative non-small cell lung cancer patients |
| Q35167933 | Role of Bcl-2 as a prognostic factor for survival in lung cancer: a systematic review of the literature with meta-analysis |
| Q35216052 | The role of HER-2/neu expression on the survival of patients with lung cancer: a systematic review of the literature |
| Q24650902 | The role of RAS oncogene in survival of patients with lung cancer: a systematic review of the literature with meta-analysis |
| Q35013566 | The role of new agents in the treatment of non-small cell lung cancer. |
| Q37553880 | Uterine leiomyosarcoma management, outcome, and associated molecular biomarkers: a single institution's experience |
| Q38669765 | Whole-genome sequencing revealed novel prognostic biomarkers and promising targets for therapy of ovarian clear cell carcinoma. |
| Q63254012 | c-erbB-2 protein in serum of primary lung cancer patients |
Search more.